Novo Nordisk A/S (NVO)
Novo Nordisk A/S Statistics
Share Statistics
Novo Nordisk A/S has 4.41B shares outstanding. The number of shares has increased by -1.8% in one year.
| Shares Outstanding | 4.41B |
| Shares Change (YoY) | -1.8% |
| Shares Change (QoQ) | -2.35% |
| Owned by Institutions (%) | 7.58% |
| Shares Floating | 4.41B |
| Failed to Deliver (FTD) Shares | 94.95K |
| FTD / Avg. Volume | 1.09% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 27.32 and the forward PE ratio is 1.82. Novo Nordisk A/S's PEG ratio is 0.19.
| PE Ratio | 27.32 |
| Forward PE | 1.82 |
| PS Ratio | 9.5 |
| Forward PS | 0.5 |
| PB Ratio | 19.23 |
| P/FCF Ratio | 39.61 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Novo Nordisk A/S has an Enterprise Value (EV) of 2,846.6B.
| EV / Sales | 9.8 |
| EV / EBITDA | 20.72 |
| EV / EBIT | 23.53 |
| EV / FCF | 40.86 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.74 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 1.48 |
| Interest Coverage | 78.26 |
Financial Efficiency
Return on Equity is 70.38% and Return on Invested Capital is 38.99%.
| Return on Equity | 70.38% |
| Return on Assets | 21.68% |
| Return on Invested Capital | 38.99% |
| Revenue Per Employee | $3.81M |
| Profits Per Employee | $1.32M |
| Employee Count | 76,302 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | 26.2B |
| Effective Tax Rate | 20.6% |
Stock Price Statistics
The stock price has increased by -51.08% in the last 52 weeks. The beta is 0.25, so Novo Nordisk A/S's price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -51.08% |
| 50-Day Moving Average | 74.73 |
| 200-Day Moving Average | 103.48 |
| Relative Strength Index (RSI) | 40.19 |
| Average Volume (20 Days) | 8.72M |
Income Statement
In the last 12 months, Novo Nordisk A/S had revenue of 290.4B and earned 100.99B in profits. Earnings per share was 22.67.
| Revenue | 290.4B |
| Gross Profit | 245.88B |
| Operating Income | 128.34B |
| Net Income | 100.99B |
| EBITDA | 137.38B |
| EBIT | 128.83B |
| Earnings Per Share (EPS) | 22.67 |
Balance Sheet
The company has 15.65B in cash and 102.79B in debt, giving a net cash position of -87.13B.
| Cash & Cash Equivalents | 15.65B |
| Total Debt | 102.79B |
| Net Cash | -87.13B |
| Retained Earnings | 144.45B |
| Total Assets | 465.8B |
| Working Capital | -56.63B |
Cash Flow
In the last 12 months, operating cash flow was 120.97B and capital expenditures -51.31B, giving a free cash flow of 69.66B.
| Operating Cash Flow | 120.97B |
| Capital Expenditures | -51.31B |
| Free Cash Flow | 69.66B |
| FCF Per Share | 15.64 |
Margins
Gross margin is 84.67%, with operating and profit margins of 44.19% and 34.78%.
| Gross Margin | 84.67% |
| Operating Margin | 44.19% |
| Pretax Margin | 43.8% |
| Profit Margin | 34.78% |
| EBITDA Margin | 47.31% |
| EBIT Margin | 44.19% |
| FCF Margin | 23.99% |
Dividends & Yields
NVO pays an annual dividend of $1.61, which amounts to a dividend yield of 2.32%.
| Dividend Per Share | $1.61 |
| Dividend Yield | 2.32% |
| Dividend Growth (YoY) | 18.21% |
| Payout Ratio | 46.18% |
| Earnings Yield | 3.66% |
| FCF Yield | 2.52% |
Analyst Forecast
The average price target for NVO is $160, which is 157.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $160 |
| Price Target Difference | 157.9% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Sep 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.34 |
| Piotroski F-Score | 6 |